A5048928370- Monoclonal and Polyclonal Antibodies Research
- MicroRNA in disease regulation
- Silymarin and Mushroom Poisoning
- Toxin Mechanisms and Immunotoxins
- Cancer-related molecular mechanisms research
- Glycosylation and Glycoproteins Research
- Multiple Myeloma Research and Treatments
- Circular RNAs in diseases
- RNA Research and Splicing
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Testicular diseases and treatments
- Colorectal Cancer Surgical Treatments
- Brain Metastases and Treatment
- Cancer Mechanisms and Therapy
- Advanced Radiotherapy Techniques
- RNA modifications and cancer
- Biopolymer Synthesis and Applications
- Bioinformatics and Genomic Networks
- Gene expression and cancer classification
- PI3K/AKT/mTOR signaling in cancer
- Forensic Toxicology and Drug Analysis
- Colorectal and Anal Carcinomas
- NF-κB Signaling Pathways
- Hedgehog Signaling Pathway Studies
Affimed Therapeutics (Germany)
2023
Universitätsmedizin Göttingen
2022
Heidelberg Pharma (Germany)
2017-2020
Max Planck Institut für Zellbiologie
2019
German Cancer Research Center
2014-2018
Heidelberg University
2014-2018
University Hospital Ulm
2016
DKFZ-ZMBH Alliance
2014-2015
National Center for Tumor Diseases
2014
Medizinische Hochschule Hannover
2014
Abstract Aggressive breast cancer is associated with poor patient outcome and characterized by the development of tumor cell variants that are able to escape from control immune system or resistant targeted therapies. The complex molecular mechanisms leading therapy resistance incompletely understood. We have previously shown high miR-519a-3p levels survival in cancer. Here, we demonstrate confers apoptosis induced TRAIL, FasL granzyme B/perforin interfering signaling cells. MiR-519a-3p...
The tumor microenvironment (TME) has an impact on breast cancer progression by creating a pro-inflammatory milieu within the tumor. However, little is known about roles of miRNAs in cells TME during this process. We identified six putative oncomiRs dataset, all strongly correlating with poor overall patient survival. Out candidates, miR-1246 was upregulated aggressive subtypes and expressed at highest levels mesenchymal stem/stroma (MSCs). Functionally, led to p65-dependent increase...
Despite major treatment advances in recent years, patients with multiple myeloma inevitably relapse. The RNA polymerase II complex has been identified as a promising therapeutic target both proliferating and dormant cancer cells. Alpha-amanitin, toxin so far without clinical application due to high liver toxicity, specifically inhibits this complex. Here, we describe the development of HDP-101, an anti-B-cell maturation antigen (BCMA) antibody conjugated amanitin derivative. HDP-101...
// Uwe Schirmer 1 , Kai Doberstein Anne-Kathleen Rupp Niko P. Bretz Daniela Wuttig 2 Helena Kiefel Christian Breunig 5 Heidi Fiegl 3 Elisabeth Müller-Holzner Robert Zeillinger 4 Eva Schuster Alain G. Zeimet Holger Sültmann and Peter Altevogt Department of Translational Immunology, German Cancer Research Center; Working Group Genome Research, Gynecology Obstetrics, Medical University Innsbruck, A-6020 Austria, Vienna, Austria; Division Molecular Analysis, Center, Heidelberg, Germany...
Breast cancer is the most common in women worldwide. The tumor microenvironment contributes to progression by inducing cell dissemination from primary and metastasis. TGF β signaling involved breast specifically elevated during metastatic transformation aggressive cancer. In this study, we performed genomewide correlation analysis of TGFBR 2 expression a panel 51 lines identified that MET coregulated with . This was confirmed at protein level human tissues. Flow cytometric luminal basal‐like...
Small molecule inhibitors of the mitogen-activated protein kinase (MAPK) pathway, such as sorafenib, represent novel treatment options for advanced hepatocellular carcinoma. The aim our study was to identify downstream targets biomarker candidates that are directly linked oncogenic MAPK pathway in carcinoma and correlate with inhibition this by multikinase inhibitors.Hepatocellular cell lines fresh tumor tumor-free liver tissues from patients were incubated different BRaf or MEK analyzed...
A non-internalizing conjugate targeting α<sub>v</sub>β<sub>3</sub> integrin inhibits the proliferation of integrin-expressing cancer cells in presence β-glucuronidase.
e14527 Background: Currently, numerous antibody-drug conjugates (ADCs) are evaluated for hematologic malignancies with toxic payloads mainly affecting only proliferating cells, and thus resulting in limited efficacy diseases low proliferation. We focus on amanitin based ADCs (ATACs: antibody-targeted Amanitin conjugates) targeting BCMA (B Cell Maturation Antigen; CD269). binds to RNA pol II thereby inhibits the cellular transcription process at very concentrations independent of cell is...
Abstract Background: ATACs (antibody-targeted Amanitin conjugates) comprise a new class of antibody-drug conjugates using as toxic payload. binds to the eukaryotic RNA pol II and thereby inhibits cellular transcription process at very low concentrations. In current study, in vitro vivo data an ATAC targeting PSMA (prostate specific membrane antigen) are presented. is predominantly expressed on malignant prostate cells carcinoma correlates with tumor progression. Hence it considered...
Abstract microRNAs (miRNAs) sind kleine, nicht für Proteine codierende RNAs, die wichtige biologische Prozesse regulieren. Neben Funktionen in der natürlichen Entwicklung von Lebewesen auch Beteiligungen an Kranksheitsprozessen wie Krebs beschrieben worden. Diese Regulation erfolgt durch Basenpaarung mit mRNAs Zielgenen, und führt entweder zu deren Abbau oder einer Blockade Herstellung diesen codierten Proteinen. Da innerhalb miRNAs nur eine sehr kurze, etwa 6‐7 Nukleotide lange...
<p>Supplementary Table and Figures</p>
<p>Supplementary Table and Figures</p>
<div>Abstract<p>Despite major treatment advances in recent years, patients with multiple myeloma inevitably relapse. The RNA polymerase II complex has been identified as a promising therapeutic target both proliferating and dormant cancer cells. Alpha-amanitin, toxin so far without clinical application due to high liver toxicity, specifically inhibits this complex. Here, we describe the development of HDP-101, an anti–B-cell maturation antigen (BCMA) antibody conjugated amanitin...
<div>Abstract<p>Despite major treatment advances in recent years, patients with multiple myeloma inevitably relapse. The RNA polymerase II complex has been identified as a promising therapeutic target both proliferating and dormant cancer cells. Alpha-amanitin, toxin so far without clinical application due to high liver toxicity, specifically inhibits this complex. Here, we describe the development of HDP-101, an anti–B-cell maturation antigen (BCMA) antibody conjugated amanitin...